English
繁體中文
Menu
About
Our Company
Our Vision
Our Organization
Leader Ship
Board
Management
Our Timeline
Pipeline
Trials
Schizophrenia Trials
Depression trials
Dementia Trials
Newsroom
Press Releases
In The News
Official Announcement
Investors
Partner
Contact
Careers
Benefits
When the Patient Is
You or Someone You Love
Press Releases
TFDA Approves SyneuRx to Conduct Phase IIb/III Clinical Trials for its Drug Candidates Treating Schizophrenia
Ω-NaBen, the Ultimate and Supreme Sodium Benzoate
US FDA Approves SyneuRx’s IND Application for a First-in-Human, Proof of Principle Clinical Trial for Patients with Early and Mild COVID-19
R&D
LEARN MORE
Trials
LEARN MORE
Press Releases
LEARN MORE
English
繁體中文
